We began to close some of these accounts in July. “Our second quarter total revenue was negatively impacted by longer than expected Enterprise sales cycles in several large prospective accounts. Hired Brian Testa as Chief People Officer Promoted Jeffrey Sirek to Chief Commercial Officer
#Icad contact full#
Received CE Mark approval for ProFound AI ® Version 3.0 for 3D MammographyĬompany’s third-generation AI solution offers significant improvement in algorithm specificity performance and faster processing time compared to the prior versionsĮnhanced our senior leadership, includingĪppointed Charles Carter as full time Chief Financial Officer Signed a global distribution agreement with Sectra, a leading international medical imaging IT and cybersecurity company, expanding access to ProFound AI ® and ProFound AI ® Risk to additional facilities and imaging centers worldwide Showed continued strength in the Therapy business with $3 million in revenues, which represents 3.8% growth over a very strong first quarter, driven largely by the continued surge in dermatology controller installations reflecting positive shifts in market dynamics and Europe, with approximately 250 software licenses installed to date Continued market penetration with ProFound AI ® Risk, the first and only commercially available clinical decision support tool providing two-year breast cancer risk estimation personalized for each woman, for 2D mammography in the U.S.